冠科生物

OX40 is now at the forefront of what has been called “T cell co-stimulation”. Immune co-stimulators work by providing the signal that promotes the expansion and proliferation of killer CD8 and helper CD4 T cells. Our latest blog post gives you the full breakdown of the OX40 receptor and its binding partner, OX40-Ligand (OX40L), including: ??Targeting OX40 in preclinical studies: improved tumor free survival and immune memory response ??Treg cell effects – both depletion and expansion observed ??Clinical trials ongoing including combination therapy Learn more about OX40 Agonists ??https://hubs.la/Q02YT3ff0

We offer targeted solutions with our extensive collection of resistance models, including specialized tools for KRASG12C and PARP inhibitor-resistant tumors. These models are designed to help you unlock key insights into resistance mechanisms and efficacy evaluation, providing a solid foundation for advancing next-generation anticancer therapies. Enhance your research with free resources showcasing our resistance models: ??AACR 2024 Poster 538 - Establishment of PARP Inhibitor-Induced Resistant Patient-Derived Ovarian Cancer Xenograft Models ?? https://hubs.la/Q02YT2dx0 ??Application Note - Breaking the Barrier of KRASG12C Inhibitor Resistance: Developing KRASG12C Inhibitor-Resistant Tumor Models ?? https://hubs.la/Q02YSYZD0 ??AACR 2024 Poster 1942 - Developing KRAS G12C Inhibitor-Resistant Tumor Models for Efficacy Evaluation of Next-Generation Anticancer Therapies ?? https://hubs.la/Q02YT43B0

We're heading to the Tumour Models London Summit! Meet our colleague Sarah Wagner, from 4th - 5th December to network and learn more about how to de-risk your studies with our services, including: ?Our customized integrated solutions, with a comprehensive suite of resistance models across in vitro, in vivo, ex vivo, and in silico platforms, supported by a living biobank of over 30 cancer types. ?Our ongoing R&D to expand our catalog, with custom model development to meet your research needs. ?Integrating biomarker strategies, to help predict clinical responses, enabling the identification of translatable solutions Schedule a meeting in advance! https://hubs.la/Q02YWNvY0

??Our virtual event is live tomorrow!?Register: https://hubs.la/Q02XwsT30 and join our expert-led webinar to learn everything you need to know about PDX mouse clinical trials - from selecting the right models and designing your study, to analyzing data for actionable insights. Register now - don't miss this opportunity to take your research to the next level!????https://hubs.la/Q02XwsT30

Access our latest immuno-oncology scientific data presented during SITC 2024, across 4 poster sessions. Browse and download the posters to discover innovative research, including: ??A High-Content Screening Platform for Testing Immunotherapies in 100 Patient-Derived Organoid Models ??A Novel In Vitro Assay to Evaluate the Potency of Anti-PD-1 and Anti-PD-L1 Drugs in NSCLC ??3D Ex Vivo Patient Tissue Platform Feasibility for Testing Drug Responses in Primary and Metastatic Colorectal Cancer ??Incorporating Virtual Control Groups in Preclinical Mouse Studies: A Historical Data Approach Browse and download the full collection https://hubs.la/Q02YJKM30 Society for Immunotherapy of Cancer (SITC)

Multi-drug combination screening studies along with novel high content?technologies are being used to identify promising multi-drug combination regimens?more efficiently. However, these study designs are highly dependent on the research question(s) being asked, so prior to embarking on a new study, we suggest getting in touch with our experts in combination drug study design to ensure your study is optimized for success. We can support you with novel combination strategies, to optimize your research and enhance cancer treatment outcomes. Discover the power of combination therapies: https://hubs.la/Q02Yxt2b0

Mouse Clinical Trials (MCTs) are a cornerstone of preclinical oncology research, providing valuable insights into drug efficacy and biomarker discovery. However, the success of these trials hinges on precise study design, appropriate model selection, and rigorous data analysis. In our latest blog post, we’ll explore how to optimize each step of MCTs, from selecting the right indications to refining biomarker discovery. You'll understand how best to leverage key bioinformatics to drive data-based decisions that speed time to clinic and set your trial up for the greatest chance of success. Learn more ?? https://hubs.la/Q02YxyqZ0

It's World Pancreatic Cancer Day. The disease is challenging to detect at an early stage and no clinically relevant diagnostic test can reliably detect early-stage pancreatic cancer in individuals without symptoms. However, JSR Life Sciences, the parent company of Crown Bioscience, have developed a novel and unique in vitro pancreatic cancer early detection technology (iv-PCED) that has great potential for detecting pancreatic cancer in its early stages. This novel iv-PCED can play a significant role in the growing field of early cancer detection, for example, akin to other commercially available cancer diagnostic tests. Read more ??https://hubs.la/Q02YfhpJ0 #PanCANawareness Pancreatic Cancer Action Network

As you progress your studies, you can work around the cancer immunity cycle with our comprehensive capabilities across platforms under one roof, designed to support immuno-oncology (IO) research. Download our free resources to learn more. ?? ??White Paper: When and How to Use Tumor Organoids in Drug Discovery https://hubs.la/Q02YmX_60 ??Application Note: In Vitro and Ex Vivo Immuno-Oncology Drug Discovery https://hubs.la/Q02YmXpL0 See how your IO studies can benefit from our cost-effective models: https://hubs.la/Q02YmYJM0

Day 2 at AACR’s Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation. If you’re also attending, feel free to reach out to me or my colleague Sadaf M. — we’d love to connect! #AACR #LiquidBiopsy #CancerResearch #IndivumedServices #CrownBiocience